Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: Prediction of the equivalent AUC/MIC breakpoints and equiefficient doses

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 5, 2000, Pages 725-732

  Firsov, Alexander A ^a,b   Lubenkoa, Irene Yu ^a   Vostrov, Sergey N ^a   Kononenko, Olga V ^a   Zinner, Stephen H ^b   Portnoy, Yury A ^a  

^a Scientific and Technological Centre Lekbiotech   (Russian Federation)

^b MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; TROVAFLOXACIN;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HALF LIFE; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PHARMACODYNAMICS; STAPHYLOCOCCUS AUREUS;

EID: 0033736779     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.5.725     Document Type: Article

References (42)

1. In vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model
2. Bactericidal activity of BAY 12-8039 against β-lactam and vancomycin-resistant staphylococci, pneumococci and enterococci
3. Pharmacodynamics of moxifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
4. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection
5. Moxifloxacin and trovafloxacin: Effect of human serum on bactericidal activity against Klebsiella pneumoniae
6. Pharmacodynamic activity of BAY 12-8039 in an in vitro model against Gram-positive and Gram-negative pathogens
7. Pharmacodynamic activity of moxifloxacin in an in vitro model against Gram positive and Gram negative pathogens
8. Bactericidal activity of moxifloxacin against Staphylococcus aureus and β-hemolytic straptococci explored using a pharmacodynamic model of infection
9. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model
10. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model
11. A new approach to in-vitro comparisons of antibiotics in dynamic models: Equivalent AUC/MIC breakpoints and equi-efficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities
12. Inter-and intraquinolone predictors of antimicrobial effect in an in-vitro dynamic model: New insight into a widely used concept
13. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
14. In vitro activity of Bay 12-8039, a novel fluoroquinolone antimicrobial agent
15. Comparative in vitro activity of moxifloxacin against maxillary sinus pathogens
16. Comparative in vitro activity of moxifloxacin, trovafloxacin and quinupristin-dalfopristin against staphylococci
17. In vitro activity of moxifloxacin compared with other fluoroquinolones against bacterial strains from upper and lower respiratory tract infections in general practice
18. Comparative activity of quinolone compounds moxifloxacin, grepafloxacin, trovafloxacin, levofloxacin, sparfloxacin, ofloxacin and the oxazolidinone linezolid against unrelated clinical isolates of and -sensitive Staphylococcus aureus
19. Activity of moxifloxacin and other fluoroquinolones against speciated staphylococci and potential of staphylococci to develop resistance
20. Comparative in vitro activity of moxifloxacin against respiratory tract pathogens
21. In vitro activity of moxifloxacin against Gram-positive bacteria
22. Correlation of MIC values of five fluoroquinolones with mutations within grlA, grlB, gyrA, gyrB in 116 unrelated clinical isolates of Staphylococcus aureus
23. In vitro activity of various antimicrobials against 194 unrelated clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates and stability of MIC values in 125 clonally related clinical MRSA
24. In vitro activity of Bay 12-8039, a novel 8-methoxyquinolone, against species representative of respiratory tract pathogens
25. In vitro activity of moxifloxacin (Bay 12-8039) against Gram-positive clinical isolates
26. Comparative in vitro activity of grepafloxacin and comparators against E. coli, K. pneumoniae, P. aeruginosa, H. influenzae, M. catarrhalis, S. aureus and S. pneumoniae
27. Comparative activity of clinafloxacin against gram-positive and -negative bacteria
28. A European multicentre study of the comparative in vitro susceptibility of Gram-positive bacteria to levofloxacin
29. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections
30. Comparative in vitro activity of gatifloxacin, a new fluoroquinolone antimicrobial, against gram-positive bacteria
31. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in-vitro dynamic model
32. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects
33. Pharmacokinetics (PK) and tolerability of the new methoxyquinolone BAY 12-8039: 10 days treatment at 400 mg daily
34. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects
35. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine
36. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
37. Safety and pharmacokinetics of multiple once-daily 750 mg intravenous doses of levofloxacin in healthy volunteers
38. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects
39. Pharmacodynamics of the fluoroquinolones
40. The clinical pharmacokinetics of levofloxacin
41. In vitro evalution of pharmacodynamic outcome parameters for fluoroquinolones against Streptococcus pneumoniae
42. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model